Mar. 12 at 1:27 PM
$ALT @2MargaritaLunch Chop, this kind of post is EXACTLY why the
$ALT board continues to remain disconnected on
$ALT's reality. Let me help:
1) Statistically, drugs that received BTD have a 65-72% probability for approval compared to 50-60% for Phase 3 drugs, overall. 46% BTDs are in Oncology.
2) Current 4 drugs in the MASH sector with BTD (Including
$IVA, which leads in Fibrosis Improvement, and
$SGMT, which shows excellent results with
$MDGL).
3) No MASH drug that has applied for BTD has been denied. This is expected given the early stages of sector development and multiple (potential) MOAs.
So thanks for sharing your hopium of success based on receiving BTD, but I think right-sizing those expecations for
$ALT is more warranted than most, especially given they are significantly lagging behind excellent performing companies that are significantly further along than
$ALT
Cheers!
